EDISON, N.J., Dec. 14, 2016 /PRNewswire/ – After evaluating each MTF Wound Care allograft in several areas – including safety, quality and effectiveness – a panel of podiatric physicians from the American Podiatric Medical Association (APMA) has granted MTF Wound Care their Seal of Approval for its AmnioBand® family of placental allografts and AlloPatch® Pliable tissue forms.
MTF Wound Care, a division of the Musculoskeletal Transplant Foundation (MTF), is a non-profit organization offering highly advanced, safe, clinically proven and cost-effective allograft solutions.
"Receiving the APMA Seal of Approval gives podiatrists and clinicians the confidence that AmnioBand and AlloPatch Pliable are beneficial in healing patients' wounds," said Kim Rounds, Vice President, MTF Wound Care. "Placing our tissues through the APMA's detailed evaluation demonstrates our commitment to be a partner of choice. We are proud of this notable accomplishment that recognizes the strength of our portfolio."
As a primary resource for foot and ankle health information, the American Podiatric Medical Association (APMA) is the nation's leading and recognized professional organization for doctors of podiatric medicine (DPMs).
"Podiatrists play a critical role in healing life- and limb-threatening wounds in patients with diabetes," said APMA President R. Daniel Davis, DPM. "We depend on cutting-edge products, devices, and treatments to help us deliver outstanding care and reduce amputations and hospitalizations. APMA is pleased to award its Seal of Approval to MTF's AlloPatch Pliable and AmnioBand tissue forms."
The APMA Seal of Approval is granted to products that are beneficial to foot health. Companies must provide comprehensive information on each product: objective data from clinical and/or laboratory studies, intended use, patents, composition, and evidence of quality control. A detailed review is conducted by each committee member, and a recommendation is then sent to the APMA Board of Trustees, which may either accept or reject the recommendation.
About AmnioBand and AlloPatch Pliable
AmnioBand is offered in several forms, derived from dehydrated human placental tissue comprised both of the amnion and chorion layers. It is used as a scaffold for the treatment of chronic non-healing wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers. AmnioBand is aseptically processed, stored in ready to use "package to patient" configuration, and available in a variety of sizes.
AlloPatch Pliable is an acellular human dermal graft designed to support host tissue remodeling. It has an open architecture derived from a deeper layer in the dermal tissue, bringing faster graft incorporation and supporting repopulation and revascularization in host tissue. It is also aseptically processed to preserve the graft's natural structure.
About MTF Wound Care
MTF Wound Care is a division of the Musculoskeletal Transplant Foundation, a non-profit organization based in Edison, NJ. MTF is a national consortium comprised of leading organ procurement organizations, tissue recovery organizations and academic medical institutions. For more, visit www.mtfwoundcare.org.
About the American Podiatric Medical Association
Founded in 1912, the American Podiatric Medical Association (APMA), headquartered in Bethesda, MD, is the leading resource for foot and ankle health information. Currently, the organization represents a vast majority of the estimated 15,000 podiatrists in the country. In addition to the national headquarters, APMA boasts 53 state component locations throughout the United States and its territories, as well as affiliated societies. For more, visit www.apma.org.
Contact: Cheri Lane
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mtf-wound-cares-amnioband-and-allopatch-pliable-receive-the-american-podiatric-medical-association-seal-of-approval-300378177.html
SOURCE MTF Wound Care